Tagged with UK

UK Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by 2022. However, despite possessing the innovators, the infrastructure and the coverage, the UK’s thriving vaccine industry risks being blown off…

UK Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and meet current health needs. Lundbeck is now focused on four key CNS areas: depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease.…

UK Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as a homegrown British biotech with confidence. Its CEO Andrew Hotchkiss also shares some of the up-coming investigation programmes for Immunocore’s…

UK Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains why the momentum is right for the UK to lead the way in sustainable healthcare and how it can remain…

UK Stewart Pearce, managing director of Otsuka UK and Ireland since 2017 discloses how he built up a leadership team fit for the Otsuka of 2023 and highlights what he appreciates about working for a Japanese pharmaceutical company. He says that at Otsuka, people are encouraged to think for themselves, be…

UK As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical industry and the patients who rely on it are under serious threat from Brexit” Erik Nordkamp, Pfizer Erik Nordkamp, the…

Portugal Nelson Pires provides an insightful update on Portugual’s pharmaceutical market evolution as well as Jaba Recordati’s ambitious Portuguese affiliate. Pires shares that diversification is one technique of navigating the market, introduces their expansion into a new therapeutic area, and explains the affiliate’s new venture into Nigeria. Would you be able…

UK Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug discovery profile post-Brexit.  Could you please start by introducing the MDC? “We believe that the future is going to be…

UK Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how the company is looking at Brexit as a glass half full. Eisai views Brexit as an opportunity to bring with…

Europe The top spenders on pharma R&D in Europe for 2015 were Switzerland – which spent over EUR 6.5 billion – followed by Germany – which spent EUR 6.2 billion – and the UK – which spent EUR 5.8 billion.

Spain Eva Prada, director of the British Chamber of Commerce in Spain, discusses trade relations between the UK and Spain and the activities of the Chamber in developing trust-based business relationships between companies and the government, their collaboration with key institutions such as ICEX, as well as their intention to work…

Europe The most valuable pharma markets in Europe for 2015. Germany leads the way, followed by France, Italy and the UK. For more pharma facts and figures, click here.